Exelixis to Release Second Quarter 2018 Financial Results on Wednesday, August 1, 2018
July 17 2018 - 4:05PM
Business Wire
– Conference Call and Webcast to Follow at 5:00
p.m. EDT/ 2:00 p.m. PDT –
Exelixis, Inc. (Nasdaq: EXEL) announced today that its second
quarter 2018 financial results will be released on Wednesday,
August 1, 2018 after the markets close. At 5:00 p.m. EDT / 2:00
p.m. PDT, Exelixis management will host a conference call and
webcast to discuss the results and provide a general business
update. Access to the event is available via the Internet from the
company’s website.
To access the webcast link, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to the conference call to ensure
adequate time for any software download that may be required to
listen to the webcast. Alternatively, please call 855-793-2457
(domestic) or 631-485-4921 (international) and provide the
conference call passcode 5668207 to join by phone.
A telephone replay will be available until 8:30 p.m. EDT on
August 3, 2018. Access numbers for the telephone replay are:
855-859-2056 (domestic) and 404-537-3406 (international); the
passcode is 5668207. A webcast replay will also be archived on
www.exelixis.com for one year.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model genetic systems, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. We discovered our three commercially available products,
CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC®
(cobimetinib), and have entered into partnerships with leading
pharmaceutical companies to bring these important medicines to
patients worldwide. Supported by revenues from our marketed
products and collaborations, we are committed to prudently
reinvesting in our business to maximize the potential of our
pipeline. We are supplementing our existing therapeutic assets with
targeted business development activities and internal drug
discovery – all to deliver the next generation of Exelixis
medicines and help patients recover stronger and live longer. In
July 2018, Exelixis was added to the Standard & Poor’s
(S&P) MidCap 400 index, which measures the performance of
profitable mid-sized companies. For more information about
Exelixis, please visit www.exelixis.com, follow @ExelixisInc on
Twitter or like Exelixis, Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX,
COMETRIQ and COTELLIC are registered U.S. trademarks.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180717005966/en/
Exelixis, Inc.Susan Hubbard, 650-837-8194Executive Vice
President,Public Affairs & Investor
Relationsshubbard@exelixis.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2023 to Apr 2024